[FDA Press Release, April 29, 2024 ]Today , the U.S. Food and Drug Administration took action aimed at helping to ensure the safety and effectiveness of laboratory developed tests, or LDTs, which are used in a growing number of health care decisions and about which concerns have been raised for many years. Continue reading→

Continue reading→

BioLab Sciences, an Arizona life science company with a mission to manufacture reliable and safe products with the highest quality to help optimize body performance through continuous innovation, education, superior customer service, and teamwork celebrated its 6th anniversary as it cut the ribbon on its new manufacturing facility in Mesa, Arizona.Continue reading→

Over 75 years, Medtronic has reinvented what’s possible for the world. The Medtronic Mission has fueled each step to alleviate pain, restore health, and extend life. 
Continue reading→

Join us for an enlightening discussion on maximizing your potential with in-state incubators, featuring an esteemed panel from across the state of Arizona. Panelists include Anita Bell from the University of Arizona Center for Innovation (UACI), Tom Schumann from the Center for Entrepreneurial Innovation (CEI) and Russ Yelton from Yelton and Associates. Discover how these incubators serve as fertile grounds for growth and innovation, providing invaluable support, mentorship, and resources tailored specifically to the needs of budding life science startups. Learn how strategically positioning your company within these incubators can facilitate access to crucial networks, funding opportunities, and specialized expertise.Continue reading→

SynCardia Systems, LLC., a Picard Medical Company, proudly commemorates Steve William’s remarkable 10-year journey since receiving a SynCardia Total Artificial Heart (STAH). Steve underwent the STAH implantation procedure on April 17, 2014.Continue reading→

FTC’s final rule will generate over 8,500 new businesses each year, raise worker wages, lower health care costs, and boost innovationContinue reading→

PHOENIX–Arizona’s bioscience sector has continued its sustained advancement over the past two years and established record highs for several performance metrics, at growth rates often outpacing the nation, according to the latest data analysis commissioned by the Flinn Foundation.

Arizona reached record highs in National Institutes of Health funding, bioscience jobs and wages, university research and development, and certain measures of university technology-transfer, as well as an increase in venture capital funding.

Since the launch of Arizona’s Bioscience Roadmap in 2002, performance metrics have been tracked and shared publicly by a third-party consultant. The latest analysis by TEConomy Partners released April 22 is the first since 2022.

“Arizona’s bioscience community—researchers, entrepreneurs, investors, educators, hospitals, companies, and more—has accomplished so much since the beginning of the Roadmap,” said Tammy McLeod, Ph.D., Flinn Foundation president and CEO. “The upward trajectory of metrics like new bioscience jobs and university research shows the power of collaboration across the community. And it illustrates why the Flinn Foundation is intent on renewing the Roadmap, our state’s strategic plan to enhance health outcomes and economic prospects.”Continue reading→

Arizona’s life science community gathered at Langham Logistics in Phoenix on April 18, 2024.  Attendees toured this state-of- the-art facility that serves the needs of the West Coast’s GMP and pharmaceutical industries, made connections, and learned how they can get engaged in accelerating the growth of Arizona’s life science sector.Continue reading→

TUCSON, Ariz., April 17, 2024 — Critical Path Institute (C-Path) today announced the appointment of Amanda Klein, Pharm.D., as Executive Director for its two newest public-private partnerships: the Critical Path for Lysosomal Diseases (CPLD) and the Critical Path for Alpha-1 Antitrypsin Deficiency (CPA-1) consortia . Klein brings a wealth of experience, having previously served as Executive Director of C-Path’s Transplant Therapeutics Consortium (TTC), where she orchestrated successful composite biomarker qualification submissions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency.Continue reading→